Fish Skin Company Kerecis Announces Kerecis Omega3 MicroGraft

The easy-to-use fish-skin graft fills a void as wound-treatment companies withdraw human-derived products per FDA guidance

ARLINGTON, Va. & REYKJAVIK, Iceland--(BUSINESS WIRE)--Kerecis, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, today announced the release of Kerecis^® Omega3 MicroGraft. The easy-to-use product is intact fish skin divided into fragments, which mold into wound beds. Kerecis^® Omega3 MicroGraft is appropriate for treating complex trauma and uneven wounds in operating rooms, wound centers and doctors’ offices.

In recent years, several wound-treatment companies have marketed human-derived wound-treatment products under the FDA 361 pathway. Some of those products were fragmented or processed in other ways. The FDA has stipulated that, as of May 31, 2021, human-derived products that are “more than minimally manipulated” require a drug approval. In response, many companies have taken these products off the market rather than apply for such approval. This has reduced the number of products available to treat serious wounds. Kerecis is addressing this void with the introduction of Kerecis Omega3 MicroGraft.

The easy-to-use graft is divided into small units that fill hard-to-reach areas, increasing the product’s effectiveness and improving healing. With a particle size of about 0.15 cm, Kerecis Omega3 MicroGraft can easily be applied in deep wound spaces that are not accessible to meshed or unmeshed sheets.

The product is approved for a range of wound conditions, including partial and full-thickness wounds; surgical and trauma wounds; and pressure, venous and diabetic ulcers.

“I found this product extremely easy to use,” said Ian Barron, DPM, of Clintonville/Dublin Foot & Ankle Group in Columbus, Ohio. “More importantly, I have seen even serious wounds heal quickly, some within days, without secondary procedures. The result is fewer procedures and an enhanced quality of life for our patients.”

"I am ecstatic to see the next evolution in the Kerecis product line,” said Patrick McEneaney, DPM, of the Northern Illinois Foot & Ankle Specialists in Chicago. “This product is extremely easy to use. The versatility of the Kerecis MicroGraft allows for optimal coverage of the most complex of tissue defects. I am amazed at the ability for this product to assist in tissue generation where traditional cellular tissue products have been difficult to utilize. I have seen faster healing times with less procedures leading to a sooner return to normal for my patients.”

Educational Presentation

To show how practitioners can achieve superior results using Kerecis Omega3 MicroGraft, the company is having an educational presentation on “Kerecis Omega3 MicroGraft Fish Skin in the Treatment of Complex Foot and Ankle Ulcerations.” Dr. Barron will present detailed cases where he has used the product in the treatment of complex foot and ankle ulcerations. John C. Lantis II, M.D., of Mount Sinai Hospital in New York, will moderate the session; and Kerecis founder and CEO Fertram Sigurjonsson will give opening remarks. The webinar will be June 3, 2021, at 7 p.m. ET. Registration is available here.

Kerecis Omega3 Technology

Kerecis Omega3 is intact fish skin that, when grafted onto damaged human tissue, recruits the body’s own cells and ultimately is converted into living tissue. Because no disease-transfer risk exists between cold-water fish and humans, the Kerecis fish skin is only gently processed and retains its similarity to human skin, making it an ideal skin substitute. The fish skin contains Omega3 fatty acids and multiple proteins that help the product to become incorporated into the body quickly. Clinical studies have found that the Kerecis products heal wounds faster than competitive products.

In addition to Kerecis Omega3 MicroGraft, Kerecis has three other products for surgical applications: Kerecis Omega3 OR, Kerecis Omega3 SecureMesh and the recently announced Kerecis Omega3 GraftGuide. Kerecis is now one of the top 10 companies in the biologics-skin and dermal-substitute market, according to SmartTRAK Business Intelligence.

About Kerecis

Kerecis develops products from fish skin and fatty acids that protect and regenerate human wounds and heal damaged tissue. Because there is no risk of a viral-disease transfer from Atlantic cod to humans, the fish skin needs only mild processing for medical use and maintains its natural structure and elements, including Omega3 fatty acids. The Kerecis fatty-acid-based products protect the body against bacterial and viral infections.

A progressive and innovative company, Kerecis is committed to the United Nations Sustainable Development Goals. The fish skin used in Kerecis products derives from wild and sustainable fish stock caught in pristine Icelandic waters and processed with 100% renewable energy in the town of Isafjordur, close to the Arctic Circle.